Marisa Wexler, MS,  senior science writer—

Tofacitinib, a therapy approved for certain inflammatory diseases effectively controlled symptoms of epidermolysis bullosa acquisita (EBA) in a man with the disease. The case was described as a letter to the editor titled “Treatment of Recurrent Epidermolysis Bullosa Acquisita With Tofacitinib” in JAMA Dermatology. EBA is a…

Topical morphine gel can help to ease pain related to wounds in people with epidermolysis bullosa (EB), a new report suggests. The treatment was used with good results in three EB patients in the U.K. “The case studies suggest a positive effect of topical morphine gel on painful wounds…

Blocking the activity of an immune cell receptor protein called FcyRIV prevented the development of epidermolysis bullosa acquisita in mice, a new study reports. The findings suggest this protein as a potential therapeutic target for this form of epidermolysis bullosa. The study, “Therapeutic effects of…

The effect of epidermolysis bullosa (EB) on oral health significantly affects the quality of life of children living with the disease, a recent study highlights. “The best way to help patients with EB and meet their demands is to improve daily oral hygiene habits and preventive measures (regular dental…

Filsuvez (Oleogel-S10) has been approved in Great Britain — England, Scotland and Wales — for treating wounds associated with dystrophic epidermolysis bullosa (DEB) or junctional epidermolysis bullosa (JEB) in patients ages 6 months and older. In addition to granting marketing authorization, Britain’s Medical Healthcare and Products Regulatory Agency (MHRA)…

People with dystrophic epidermolysis bullosa (DEB) saw the total surface of their wounds significantly reduced after being treated with Filsuvez (Oleogel-S10) for more than a year, new data from the EASE clinical trial show. After 15 months, these patients experienced sustained reductions of 53%, on average, in wound…

Skin tumors called cutaneous squamous cell carcinomas (cSCCs) are common in people with certain types of epidermolysis bullosa (EB), and their surgical management is often complex, a study highlights. Its researchers noted that regular monitoring to enable early diagnosis is key to proper management of these tumors. “Our…

Treatment with the experimental protein replacement therapy PTR-01 promoted wound healing and decreased pain in people with recessive dystrophic epidermolysis bullosa (RDEB), new results from a Phase 2 clinical trial show. The findings were presented by BridgeBio Pharma and its affiliate, Phoenix Tissue Repair, the therapy’s developer, at…

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

The antibiotic gentamicin, given via an infusion into the bloodstream, promoted wound closure and increased the production of laminin 332 in five children with junctional epidermolysis bullosa (JEB) in a small clinical trial. Its researchers called for further study into this treatment as a potential long-term therapy for JEB. Results…

Treatment with ointment containing a low dose of calcipotriol — an analog (similar compound) of vitamin D3 — helped to speed wound closure and reduce itching in people with dystrophic epidermolysis bullosa (DEB) in a clinical trial. “While corroboration of our results by large-scaled studies is pending, our preliminary…

Treatment with Abeona Therapeutics‘ investigational cell therapy EB-101 led to successful wound healing and eased pain in seven adults with recessive dystrophic epidermolysis bullosa (RDEB) who were followed for up to six years in a clinical trial. “The updated Phase 1/2a results showed safety and durable efficacy…